Company intelligence / Profile preview

Spiral Biotech

South San Francisco, California, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Spiral Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies for inner ear disorders, including hearing loss and Ménière's disease. The company's proprietary Minimally Invasive Cochlear System (MICS) platform enables the precise and durable delivery of drugs to the cochlea, overcoming the physiological barriers of the inner ear. Its lead candidate, SPT-2101, is a sustained-release formulation of dexamethasone currently in Phase 2 clinical trials for the treatment of Ménière's disease. Spiral's approach combines advanced drug delivery technology with proven therapeutic agents to address significant unmet needs in otology.

Therapeutic areas: Neurology
Modalities: Small moleculeHydrogel-based drug delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Spiral Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spiral Biotech.

Explore the full profile